|Awarded On||November 19, 2015|
|Title||Identifying new epigenetic vulnerabilities in pancreatic cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Giulio F Draetta|
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death, and only 7% of patients survive 5 years after diagnosis. Several mutations have been identified that drive PDAC development, with a critical mutation in the KRAS gene involved in >90% of all tumors. This mutation, along with other genes that are commonly mutated in PDAC, have made these tumors especially recalcitrant to so-called targeted therapies, which are drugs that target a specific protein, and no significant improvement in clinical outcomes has been gained in recent years. To approach the problem of designing new targeted therapies for patients with PDAC differently, we validated and optimized a no...